Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -2.26% 86.50 86.00 87.00 90.00 86.00 89.00 408,839 16:10:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.4 -4.5 -14.0 - 45

Genedrive Share Discussion Threads

Showing 3276 to 3298 of 3300 messages
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older
DateSubjectAuthorDiscuss
10/8/2020
07:14
Not sure if it is even relevant as GDR are making tests. Also a fully working vaccine could be 6+ months away
ihavenoclue
09/8/2020
09:20
Another one for the bin - filtered
petersinthemarket
08/8/2020
20:48
COVID No prizes for the losers in the race for the #vaccine https://tinyurl.com/y2cu6nsb
sharenow1
08/8/2020
12:30
Now that their subsidiary Beckman Coulter have done the collaboration deal with GDR, is there any reason why Danagher would not want to have Genedrive in their group of companies? Just don't be surprised to see a buyout offer on the table soon....!
swerves1
07/8/2020
21:04
Redx Many sector-mates have seen their value rocket on the back of projects related to the pandemic: Genedrive Avacta Omega have soared 860%, 760% and 580% respectively with their tests. Tiziana Life grew four-fold 15:27, 7 August 2020 https://tinyurl.com/yxpyamz4
dealmein
07/8/2020
14:31
News on big orders coming here soon imo...through Beckman Coulter in the US. And India too.Let's not forget, Bill Gated co. GHIF are holding onto their 14%. So GDR have major backing with these two.Could be RNS early next week.....to blow £1 far away...!
swerves1
07/8/2020
11:36
David Budd, Chief Executive Officer of genedrive plc, said "We are very pleased to have the opportunity to work with Beckman Coulter in delivering an innovative high throughput COVID-19 PCR solution. It's been our focus to work with a top tier, high throughput lab automation partner like Beckman to drive uptake of our test and further differentiate our unique capabilities in the market. The combination of our ready to use chemistry with robotics and on-board RNA extraction would give laboratories a unique and rapid workflow that can achieve impressive throughput and result turnaround times. We are both working to have the ongoing validation completed in approximately 6 weeks, with initial introduction in the USA at an already identified clinical laboratory." 5 weeks to go. Fingers crossed.
deanmatlazin
07/8/2020
11:35
Greg Milosevich, President at Beckman Coulter Life Sciences, said "The integration of Beckman Coulter Life Sciences' and genedrive's technologies produces a formidable workhorse solution for specialized laboratories looking to establish new or next level laboratory automation with labor cost reduction Beckman Coulter Market Cap is £2.1 billion and has branches all over the world. Genedrive is going to get access to American Market ( + rest of the world ) via Beckman Coulter : ) I am convinced that the share price should double up soon. The placing 80p/share was 3 months ago and is not far from current price. A strong buy!!
deanmatlazin
07/8/2020
08:43
Apologies, more news today on Avacta hTtps://www.directorstalkinterviews.com/avacta-group-transfer-technology-to-bbi-solutions-for-manufacture-of-covid-19-test-interview/412849013
adnexal schevsur
07/8/2020
08:09
Nice opening.....
qs99
06/8/2020
11:05
Good price action again today. These are clearly too cheap given the news this week. Next six weeks will be interesting as per RNS
pauliewonder
06/8/2020
09:08
Apologies but don't miss out on mighty AVACTA news hTtps://www.yorkshirepost.co.uk/business/avacta-appoints-bbi-it-prepares-launch-millions-covid-19-tests-2934357
adnexal schevsur
06/8/2020
07:36
Seems Avacta are still in the proces of rgen waiting for their CE marking approval from today's rns: "Avacta aims to begin clinical validation of the test as soon as possible by using the first pilot batches generated as part of the technology transfer process for these studies. In parallel with these clinical validation studies, which will be run within the UK government's CONDOR programme and potentially with other collaborators globally, BBI will work with Avacta and Cytiva to produce the additional technical documentation that is required for CE marking of the final product. Hhttps://www.investegate.co.uk/avacta-group-plc--avct-/rns/covid-19-rapid-antigen-test-manufacturing-partner/202008060700062934V/
euclid5
05/8/2020
17:42
Neither have I, and it is frustrating to see the share price action today, but yesterday's news was such a relief now that all we have to do is wait.
ihavenoclue
05/8/2020
17:01
Cheers .... I've no intension of selling before 200 Will evaluate then. Thanks
amaretto1
05/8/2020
16:59
Amaretto, chill. Yesterday showed what GDR have been doing behind the scenes and partnering with a large US Pharm is a top move.GDR can't control the share price so let's see where we are in 6 weeks when validation is complete, and approvals have landed, and sales from the other 10 countries are known.Chin up and keep the faith.RegardsIHNC
ihavenoclue
05/8/2020
11:50
anyone of the 10,000,000 out there!
abbynat
05/8/2020
11:10
British Airways will soon be testing all passengers and crew . . . I wonder who's kit they'll go for?
suze66
05/8/2020
09:13
i'm hoping OCT!
abbynat
05/8/2020
08:20
Just picked up some more, methinks this will be through the previous high of 300p by the year end.
czar
05/8/2020
08:10
Hope it is back to £2 or more in 6 weeks time.
deanmatlazin
04/8/2020
21:52
Iam thanks for asking !
amaretto1
04/8/2020
21:15
Amar knows everything about every company!!!! Why is he not in the Bahamas living the life!!
nodoe
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older
ADVFN Advertorial
Your Recent History
LSE
GDR
Genedrive
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 22:21:39